The University of Chicago Header Logo

Mei-Yin Polley

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentPublic Health Sciences
AddressChicago IL 60637
Phone+1 (773) 8342215
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Polley’s primary research involves the design, conduct, and analysis of all phases of cancer clinical trials. She is the Head of the Statistics Division of NRG Oncology Statistics and Data Management Center (SDMC) as well as the Co-Chair of the Brain Tumor Committee of NRG Oncology, a National Cancer Institute sponsored member of the national clinical trials network group. Previously, she served as the Director of the Biostatistics and Bioinformatics Core of the Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE). Dr. Polley had served on many scientific governing or advisory bodies including the National Cancer Institute Steering Committees (breast, lymphoma, head and neck cancer, and pediatric and adolescent solid tumor), the Scientific Program Committee of American Society of Clinical Oncology (ASCO) annual meetings, and the US Veterans Affairs (VA) Oncology A Study Section. Dr. Polley’s methodological interests include early-phase clinical trial designs, biomarker reproducibility, innovative group sequential methods for biomarker validation, prognostic and predictive modeling, design and analysis of biomarker-based clinical trials, and design and monitoring of late phase clinical trials.

    Collapse Biography 
    Collapse education and training
    Harvard University, Cambridge, MassachusettsMA06/1999Statistics
    Columbia University, New York, New YorkMS05/2001Biostatistics
    Columbia University, New York, New YorkPhD06/2006Biostatistics
    Collapse awards and honors
    2001 - 2004Merck & Co., Inc. Fellowship, Columbia University
    2006The Joseph L. Fleiss Memorial Prize in Biostatistics for an Outstanding Dissertation, Columbia University
    2008Travel Award - Biostatistics Workshop, American Association for Cancer Research (AACR)
    2009Award for Excellence in Clinical Research, The American Brain Tumor Association
    2009REAC Pilot Research Award in Basic and Clinical/Translational Sciences, University of California San Francisco
    2012Distinguished Achievement Award, Kelly Government Solutions, National Cancer Institute
    2017The Fraternal Order of Eagles Cancer Research Award, Mayo Clinic Cancer Center
    2018Breast Cancer Specialized Program of Research Excellence - Developmental Research Program Award, Mayo Clinic
    2021 - 2025Appointee - Special Government Employee (SGE) member, Federal Advisory Committee Act (FACA), US Department of Veterans Affairs (VA)

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Polley MC, Schwartz D, Karrison T, Dignam JJ. Leveraging External Control Data in the Design and Analysis of Neuro-Oncology Trials: Pearls and Perils. Neuro Oncol. 2024 Jan 22. PMID: 38254183.
      Citations:    Fields:    
    2. Chen WC, Choudhury A, Youngblood MW, Polley MC, Lucas CG, Mirchia K, Maas SLN, Suwala AK, Won M, Bayley JC, Harmanci AS, Harmanci AO, Klisch TJ, Nguyen MP, Vasudevan HN, McCortney K, Yu TJ, Bhave V, Lam TC, Pu JK, Li LF, Leung GK, Chan JW, Perlow HK, Palmer JD, Haberler C, Berghoff AS, Preusser M, Nicolaides TP, Mawrin C, Agnihotri S, Resnick A, Rood BR, Chew J, Young JS, Boreta L, Braunstein SE, Schulte J, Butowski N, Santagata S, Spetzler D, Bush NAO, Villanueva-Meyer JE, Chandler JP, Solomon DA, Rogers CL, Pugh SL, Mehta MP, Sneed PK, Berger MS, Horbinski CM, McDermott MW, Perry A, Bi WL, Patel AJ, Sahm F, Magill ST, Raleigh DR. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med. 2023 Dec; 29(12):3067-3076. PMID: 37944590.
      Citations: 2     Fields:    Translation:Humans
    3. Batchelor TT, Won M, Chakravarti A, Hadjipanayis CG, Shi W, Ashby LS, Stieber VW, Robins HI, Gray HJ, Voloschin A, Fiveash JB, Robinson CG, Chamarthy U, Kwok Y, Cescon TP, Sharma AK, Chaudhary R, Polley MY, Mehta MP. NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma. Neurooncol Adv. 2023; 5(1):vdad116. PMID: 38024244; PMCID: PMC10660192.
    4. Stahlbaum D, Jablonski R, Strek ME, Bestvina CM, Polley MY, Reid P. Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis. Respir Med. 2023 Oct; 217:107330. PMID: 37385460.
      Citations:    Fields:    
    5. Porter AB, Wen PY, Polley MC. Molecular Profiling in Neuro-Oncology: Where We Are, Where We're Heading, and How We Ensure Everyone Can Come Along. Am Soc Clin Oncol Educ Book. 2023 May; 43:e389322. PMID: 37167580.
      Citations: 1     Fields:    Translation:Humans
    6. Rahman R, Polley MC, Alder L, Brastianos PK, Anders CK, Tawbi HA, Mehta M, Wen PY, Geyer S, de Groot J, Zadeh G, Piantadosi S, Galanis E, Khasraw M. Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. Lancet Oncol. 2023 Apr; 24(4):e161-e171. PMID: 36990614; PMCID: PMC10401610.
      Citations: 1     Fields:    Translation:Humans
    7. Polley MC, Gorlia T, Lassman AB, van den Bent MJ. Reply to B. Zhao et al. J Clin Oncol. 2023 Feb 01; 41(4):934-935. PMID: 36191279.
      Citations:    Fields:    
    8. Lassman AB, Hoang-Xuan K, Polley MC, Brandes AA, Cairncross JG, Kros JM, Ashby LS, Taphoorn MJB, Souhami L, Dinjens WNM, Laack NN, Kouwenhoven MCM, Fink KL, French PJ, Macdonald DR, Lacombe D, Won M, Gorlia T, Mehta MP, van den Bent MJ. Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. J Clin Oncol. 2022 Aug 10; 40(23):2539-2545. PMID: 35731991; PMCID: PMC9362869.
      Citations: 6     Fields:    Translation:Humans
    9. Polley MC. On the Quest of Risk Stratification in HER2-Positive Breast Cancer. J Natl Cancer Inst. 2022 03 08; 114(3):345-346. PMID: 33787921; PMCID: PMC8902343.
      Citations:    Fields:    Translation:Humans
    10. Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Hudis CA, Winer EP, Partridge A, Hyslop T, Carey LA, Perou CM, Sikov WM. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022 04 20; 40(12):1323-1334. PMID: 35044810; PMCID: PMC9015203.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    11. Rahman R, Ventz S, McDunn J, Louv B, Reyes-Rivera I, Polley MC, Merchant F, Abrey LE, Allen JE, Aguilar LK, Aguilar-Cordova E, Arons D, Tanner K, Bagley S, Khasraw M, Cloughesy T, Wen PY, Alexander BM, Trippa L. Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 2021 10; 22(10):e456-e465. PMID: 34592195; PMCID: PMC8893120.
      Citations: 28     Fields:    Translation:Humans
    12. Polley MC, Dickler MN, Sinnwell J, Tenner K, de la Haba J, Loibl S, Goetz MP, Bergh J, Roberston J, Couch F, Ellis MJ, Martin M. A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. Breast Cancer Res Treat. 2021 Aug; 189(1):15-23. PMID: 34218359; PMCID: PMC8691756.
      Citations: 4     Fields:    Translation:Humans
    13. Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF, Penault-Llorca FM. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021 07 01; 113(7):808-819. PMID: 33369635; PMCID: PMC8487652.
      Citations: 169     Fields:    Translation:Humans
    14. Carter JM, Polley MC, Leon-Ferre RA, Sinnwell J, Thompson KJ, Wang X, Ma Y, Zahrieh D, Kachergus JM, Solanki M, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Thompson EA, Goetz MP. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer. Clin Cancer Res. 2021 10 15; 27(20):5628-5637. PMID: 34108182; PMCID: PMC8808363.
      Citations: 19     Fields:    Translation:Humans
    15. Polley MC, Dignam JJ. Statistical Considerations in the Evaluation of Continuous Biomarkers. J Nucl Med. 2021 05 10; 62(5):605-611. PMID: 33579807; PMCID: PMC8844257.
      Citations: 10     Fields:    Translation:Humans
    16. Polley MC, Leon-Ferre RA, Leung S, Cheng A, Gao D, Sinnwell J, Liu H, Hillman DW, Eyman-Casey A, Gilbert JA, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari K, Couch F, Carter JM, Visscher DW, Nielsen TO, Goetz MP. A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. Breast Cancer Res Treat. 2021 Feb; 185(3):557-566. PMID: 33389409; PMCID: PMC7925385.
      Citations: 11     Fields:    Translation:Humans
    17. Dai B, Polley MC. Two-Stage Adaptive Design for Prognostic Biomarker Signatures with a Survival Endpoint. Stat Biopharm Res. 2022; 14(2):217-226. PMID: 35601026; PMCID: PMC9122335.
    18. Fernandez-Martinez A, Krop IE, Hillman DW, Polley MY, Parker JS, Huebner L, Hoadley KA, Shepherd J, Tolaney S, Henry NL, Dang C, Harris L, Berry D, Hahn O, Hudis C, Winer E, Partridge A, Perou CM, Carey LA. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol. 2020 12 10; 38(35):4184-4193. PMID: 33095682; PMCID: PMC7723687.
      Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
    19. Korpics MC, Polley MY, Bhave SR, Redler G, Pitroda SP, Luke JJ, Chmura SJ. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):189-195. PMID: 32569799.
      Citations: 9     Fields:    Translation:HumansCells
    20. Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, Higley HR, Kelloff G, Liu H, Zelenetz AD, Cheson BD, Wagner-Johnston N, Kahl BS, Friedberg JW, Hsi ED, Leonard JP, Schwartz LH, Wilson WH, Bartlett NL, Schöder H. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020 06 18; 135(25):2224-2234. PMID: 32232481; PMCID: PMC7316220.
      Citations: 29     Fields:    Translation:Humans
    21. Baughn LB, Li Z, Pearce K, Vachon CM, Polley MY, Keats J, Elhaik E, Baird M, Therneau T, Cerhan JR, Bergsagel PL, Dispenzieri A, Rajkumar SV, Asmann YW, Kumar S. The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. Blood Cancer J. 2020 03 16; 10(3):39. PMID: 32179748; PMCID: PMC7075993.
      Citations: 2     Fields:    Translation:Humans
    22. Norton N, Youssef B, Hillman DW, Nassar A, Geiger XJ, Necela BM, Liu H, Ruddy KJ, Polley MC, Ingle JN, Couch FJ, Perez EA, Liu MC, Carter JM, Leon-Ferre RA, Boughey JC, Somers EB, Kalari KR, Visscher DW, Goetz MP, Knutson KL. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. NPJ Breast Cancer. 2020; 6:4. PMID: 32047850; PMCID: PMC7000381.
      Citations: 19     
    23. Dai B, Polley MC. Two-Stage Adaptive Design for Prognostic Biomarker Signatures With a Survival Endpoint. Statistics in Biopharmaceutical Research. 2020. View Publication.
    24. Polley MC, Korn EL, Freidlin B. Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker Evaluation. JCO Precis Oncol. 2019; 3. PMID: 32923845; PMCID: PMC7446320.
      Citations: 4     Fields:    
    25. Polley MC, Cheung YK. Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology. JCO Precis Oncol. 2019; 3. PMID: 32923846; PMCID: PMC7446322.
      Citations: 2     Fields:    
    26. Page DB, Bear H, Prabhakaran S, Gatti-Mays ME, Thomas A, Cobain E, McArthur H, Balko JM, Gameiro SR, Nanda R, Gulley JL, Kalinsky K, White J, Litton J, Chmura SJ, Polley MY, Vincent B, Cescon DW, Disis ML, Sparano JA, Mittendorf EA, Adams S. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ Breast Cancer. 2019; 5:34. PMID: 31602395; PMCID: PMC6783471.
      Citations: 27     
    27. Taparra K, Liu H, Polley MY, Ristow K, Habermann TM, Ansell SM. Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. Leuk Lymphoma. 2020 02; 61(2):298-308. PMID: 31517559.
      Citations: 7     Fields:    Translation:Humans
    28. Muss HB, Polley MC, Berry DA, Liu H, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Kartcheske PA, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Sutton LM, Magrinat G, Parker BA, Hart RD, Grenier D, Hurria A, Jatoi A, Norton L, Hudis CA, Winer EP, Carey L. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348. PMID: 31339827; PMCID: PMC6900836.
      Citations: 25     Fields:    Translation:Humans
    29. Blum KA, Polley MY, Jung SH, Dockter TJ, Anderson S, Hsi ED, Wagner-Johnston N, Christian B, Atkins J, Cheson BD, Leonard JP, Bartlett NL. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). Cancer. 2019 10 01; 125(19):3378-3389. PMID: 31174236; PMCID: PMC6744328.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    30. Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Zelenetz AD, Leonard JP, Schöder H. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019 07 20; 37(21):1790-1799. PMID: 30939090; PMCID: PMC6774813.
      Citations: 128     Fields:    Translation:HumansCTClinical Trials
    31. Peterson JF, Rowsey RA, Marcou CA, Pearce KE, Williamson CM, Frederick LA, Greipp PT, Ketterling RP, Kumar S, Viswanatha DS, Polley MY, Fink JM, Reichard KK, Van Dyke DL, Baughn LB. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer J. 2019 02 19; 9(3):20. PMID: 30783078; PMCID: PMC6381150.
      Citations: 6     Fields:    Translation:HumansCells
    32. Yang ZZ, Kim HJ, Villasboas JC, Price-Troska T, Jalali S, Wu H, Luchtel RA, Polley MC, Novak AJ, Ansell SM. Mass Cytometry Analysis Reveals that Specific Intratumoral CD4+ T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma. Cell Rep. 2019 02 19; 26(8):2178-2193.e3. PMID: 30784598; PMCID: PMC6402596.
      Citations: 31     Fields:    Translation:HumansCells
    33. Baughn LB, Pearce K, Larson D, Polley MY, Elhaik E, Baird M, Colby C, Benson J, Li Z, Asmann Y, Therneau T, Cerhan JR, Vachon CM, Stewart AK, Bergsagel PL, Dispenzieri A, Kumar S, Rajkumar SV. Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer J. 2018 10 10; 8(10):96. PMID: 30305608; PMCID: PMC6180134.
      Citations: 29     Fields:    Translation:Humans
    34. . A simulation based evaluation of sample size methods for biomarker studies. Int J Stat Med Res. 2018; 4(7):106-116. View Publication.
    35. Leon-Ferre RA, Polley MY, Liu H, Gilbert JA, Cafourek V, Hillman DW, Elkhanany A, Akinhanmi M, Lilyquist J, Thomas A, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Visscher DW, Goetz MP. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat. 2018 01; 167(1):89-99. PMID: 28913760; PMCID: PMC5790598.
      Citations: 50     Fields:    Translation:HumansCells
    36. Polley MC. Power estimation in biomarker studies where events are already observed. Clin Trials. 2017 Dec; 14(6):621-628. PMID: 28776405.
      Citations: 3     Fields:    Translation:Humans
    37. Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JM, McShane LM, Enos RA, Badve SS, Bane AL, Borgquist S, Fineberg S, Lin MG, Gown AM, Grabau D, Gutierrez C, Hugh JC, Moriya T, Ohi Y, Osborne CK, Piper T, Porter PL, Sakatani T, Salgado R, Starczynski J, Viale G, Dowsett M, Hayes DF, Nielsen TO, Penault-Llorca FM, Lænkholm AV. An international study to increase concordance in Ki67 scoring. Mod Pathol. 2015 Jun; 28(6):778-86. PMID: 25698062.
      Citations: 83     Fields:    Translation:Humans
    38. Ionan AC, Polley MY, McShane LM, Dobbin KK. Comparison of confidence interval methods for an intra-class correlation coefficient (ICC). BMC Med Res Methodol. 2014 Nov 22; 14:121. PMID: 25417040; PMCID: PMC4258044.
      Citations: 21     Fields:    Translation:Humans
    39. Polley MY, Polley EC, Huang EP, Freidlin B, Simon R. Two-stage adaptive cutoff design for building and validating a prognostic biomarker signature. Stat Med. 2014 Dec 20; 33(29):5097-110. PMID: 25263614; PMCID: PMC4227914.
      Citations: 4     Fields:    Translation:Humans
    40. Sharon E, Polley MY, Bernstein MB, Ahmed M. Immunotherapy and radiation therapy: considerations for successfully combining radiation into the paradigm of immuno-oncology drug development. Radiat Res. 2014 Aug; 182(2):252-7. PMID: 25003314.
      Citations: 9     Fields:    Translation:HumansAnimals
    41. Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, Viale G, Zabaglo LA, Bartlett JM, Gown AM, Symmans WF, Piper T, Mehl E, Enos RA, Hayes DF, Dowsett M, Nielsen TO, International Ki67 in Breast Cancer Working Group of the Breast International Group and North Americ, Polley MY, Penault-Llorca F. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013 Dec 18; 105(24):1897-906. PMID: 24203987; PMCID: PMC3888090.
      Citations: 222     Fields:    Translation:Humans
    42. McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA. Criteria for the use of omics-based predictors in clinical trials. Nature. 2013 Oct 17; 502(7471):317-20. PMID: 24132288; PMCID: PMC4180668.
      Citations: 105     Fields:    Translation:Humans
    43. McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA. Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med. 2013 Oct 17; 11:220. PMID: 24228635; PMCID: PMC3852338.
      Citations: 54     Fields:    Translation:Humans
    44. Polley MY, Freidlin B, Korn EL, Conley BA, Abrams JS, McShane LM. Statistical and practical considerations for clinical evaluation of predictive biomarkers. J Natl Cancer Inst. 2013 Nov 20; 105(22):1677-83. PMID: 24136891; PMCID: PMC3888208.
      Citations: 61     Fields:    Translation:HumansCells
    45. McShane LM, Polley MY. Development of omics-based clinical tests for prognosis and therapy selection: the challenge of achieving statistical robustness and clinical utility. Clin Trials. 2013 Oct; 10(5):653-65. PMID: 24000377; PMCID: PMC4410005.
      Citations: 22     Fields:    Translation:Humans
    46. Bodelon C, Polley MY, Kemp TJ, Pesatori AC, McShane LM, Caporaso NE, Hildesheim A, Pinto LA, Landi MT. Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. Ann Oncol. 2013 Aug; 24(8):2073-9. PMID: 23680692; PMCID: PMC3718510.
      Citations: 21     Fields:    Translation:Humans
    47. Freidlin B, McShane LM, Polley MY, Korn EL. Randomized phase II trial designs with biomarkers. J Clin Oncol. 2012 Sep 10; 30(26):3304-9. PMID: 22869885; PMCID: PMC3434989.
      Citations: 33     Fields:    Translation:Humans
    48. Phillips JJ, Huillard E, Robinson AE, Ward A, Lum DH, Polley MY, Rosen SD, Rowitch DH, Werb Z. Heparan sulfate sulfatase SULF2 regulates PDGFRa signaling and growth in human and mouse malignant glioma. J Clin Invest. 2012 Mar; 122(3):911-22. PMID: 22293178; PMCID: PMC3287216.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    49. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 01; 29(31):4175-80. PMID: 21969507; PMCID: PMC3208537.
      Citations: 32     Fields:    Translation:Humans
    50. Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011 Dec; 13(12):1331-8. PMID: 21896554; PMCID: PMC3223090.
      Citations: 43     Fields:    Translation:HumansCellsCTClinical Trials
    51. Pejavar S, Polley MY, Rosenberg-Wohl S, Chennupati S, Prados MD, Berger MS, Banerjee A, Gupta N, Haas-Kogan D. Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy. J Neurooncol. 2012 Jan; 106(2):367-75. PMID: 21826561.
      Citations: 26     Fields:    Translation:Humans
    52. Polley MY. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities. Stat Med. 2011 Jul 30; 30(17):2130-43. PMID: 21590790; PMCID: PMC3904348.
      Citations: 13     Fields:    Translation:Humans
    53. Mueller S, Yang X, Sottero TL, Gragg A, Prasad G, Polley MY, Weiss WA, Matthay KK, Davidoff AM, DuBois SG, Haas-Kogan DA. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett. 2011 Jul 28; 306(2):223-9. PMID: 21497989; PMCID: PMC3244077.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    54. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011 Jul; 115(1):3-8. PMID: 21417701.
      Citations: 558     Fields:    Translation:Humans
    55. Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD, Haas-Kogan DA. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011 Apr; 13(4):384-92. PMID: 21317208; PMCID: PMC3064692.
      Citations: 81     Fields:    Translation:HumansAnimalsCells
    56. Parvataneni R, Polley MY, Freeman T, Lamborn K, Prados M, Butowski N, Liu R, Clarke J, Page M, Rabbitt J, Fedoroff A, Clow E, Hsieh E, Kivett V, Deboer R, Chang S. Identifying the needs of brain tumor patients and their caregivers. J Neurooncol. 2011 Sep; 104(3):737-44. PMID: 21311950; PMCID: PMC3170122.
      Citations: 19     Fields:    Translation:Humans
    57. Li Y, Lupo JM, Polley MY, Crane JC, Bian W, Cha S, Chang S, Nelson SJ. Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. Neuro Oncol. 2011 May; 13(5):546-57. PMID: 21297128; PMCID: PMC3093330.
      Citations: 25     Fields:    Translation:Humans
    58. Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MY, Sughrue ME, McDermott MW, Parsa AT, Berger MS, Aghi MK. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg. 2011 Jun; 114(6):1609-16. PMID: 21142749.
      Citations: 29     Fields:    Translation:Humans
    59. Essock-Burns E, Lupo JM, Cha S, Polley MY, Butowski NA, Chang SM, Nelson SJ. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011 Jan; 13(1):119-31. PMID: 21036812; PMCID: PMC3018901.
      Citations: 30     Fields:    Translation:Humans
    60. Tate MC, Kim CY, Chang EF, Polley MY, Berger MS. Assessment of morbidity following resection of cingulate gyrus gliomas. Clinical article. J Neurosurg. 2011 Mar; 114(3):640-7. PMID: 20932098.
      Citations: 16     Fields:    Translation:Humans
    61. Cloyd JM, Acosta FL, Polley MY, Ames CP. En bloc resection for primary and metastatic tumors of the spine: a systematic review of the literature. Neurosurgery. 2010 Aug; 67(2):435-44; discussion 444-5. PMID: 20644431.
      Citations: 31     Fields:    Translation:Humans
    62. Srinivasan R, Phillips JJ, Vandenberg SR, Polley MY, Bourne G, Au A, Pirzkall A, Cha S, Chang SM, Nelson SJ. Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neuro Oncol. 2010 Nov; 12(11):1152-61. PMID: 20647244; PMCID: PMC3098023.
      Citations: 23     Fields:    Translation:Humans
    63. Chang EF, Clark A, Smith JS, Polley MY, Chang SM, Barbaro NM, Parsa AT, McDermott MW, Berger MS. Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg. 2011 Mar; 114(3):566-73. PMID: 20635853; PMCID: PMC3877621.
      Citations: 73     Fields:    Translation:Humans
    64. Mueller S, Polley MY, Lee B, Kunwar S, Pedain C, Mittermeyer S, Westphal M, Sampson JH, Vogelbaum MA, Croteau D, Chang SM, Wembacher-Schröder E. Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol. 2011 Jan; 101(2):267-77. PMID: 20563833; PMCID: PMC2996533.
      Citations: 33     Fields:    Translation:Humans
    65. Khayal IS, Polley MY, Jalbert L, Elkhaled A, Chang SM, Cha S, Butowski NA, Nelson SJ. Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. Neuro Oncol. 2010 Sep; 12(9):908-16. PMID: 20501631; PMCID: PMC2940691.
      Citations: 17     Fields:    Translation:Humans
    66. Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M, Musib L, Nicol SJ, Thornton DE, Prados MD. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol. 2010 Jun; 12(6):608-13. PMID: 20156802; PMCID: PMC2940647.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    67. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010 Jan 15; 70(2):512-9. PMID: 20068183; PMCID: PMC2851233.
      Citations: 140     Fields:    Translation:Humans
    68. Sanai N, Polley MY, Berger MS. Insular glioma resection: assessment of patient morbidity, survival, and tumor progression. J Neurosurg. 2010 Jan; 112(1):1-9. PMID: 19612970.
      Citations: 91     Fields:    Translation:Humans
    69. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010 Mar; 12(3):274-82. PMID: 20167815; PMCID: PMC2940590.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    70. McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS, Zheng S, Lamborn KR, Wiencke JK, Chang SM, Prados MD, Berger MS, Stokoe D, Haas-Kogan DA. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol. 2010 Mar; 97(1):33-40. PMID: 19705067; PMCID: PMC2814032.
      Citations: 36     Fields:    Translation:HumansCells
    71. Liu R, Solheim K, Polley MY, Lamborn KR, Page M, Fedoroff A, Rabbitt J, Butowski N, Prados M, Chang SM. Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol. 2009 Feb; 11(1):59-68. PMID: 18713953; PMCID: PMC2718960.
      Citations: 28     Fields:    Translation:Humans
    72. Polley MY, Cheung YK. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests. Biometrics. 2008 Mar; 64(1):232-41. PMID: 17573866.
      Citations: 9     Fields:    
    Polley's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (296)
    Co-Authors (13)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors